STOCK TITAN
  1. Home
  2. News
  3. EXEL

Exelixis Inc - EXEL STOCK NEWS

Welcome to our dedicated news page for Exelixis (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exelixis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exelixis's position in the market.

News
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Rhea-AI Summary
Exelixis, Inc. (EXEL) will release its first quarter 2024 financial results on April 30, 2024, followed by a conference call and webcast to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) announces participation in investor conferences in March with webcasts available on www.exelixis.com. Management team to present at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Barclays 26th Annual Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
News
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) reported total revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023. Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023. GAAP Diluted EPS of $0.27 for the Fourth Quarter of 2023, $0.65 for the Fiscal Year 2023. Non-GAAP Diluted EPS of $0.33 for the Fourth Quarter of 2023, $0.90 for the Fiscal Year 2023. The company is focusing on advancing regulatory strategies for cabozantinib label expansions in neuroendocrine tumors and metastatic castration-resistant prostate cancer, with high unmet medical need. The financial results, growth opportunities, and regulatory strategies are significant for the company's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.56%
Tags
earnings
News
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) announced that its management team will participate in fireside chats at investor conferences in February. The company is scheduled to present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference on February 8 in New York City and at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13. Webcast links can be accessed on www.exelixis.com and replays will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
News
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Rhea-AI Summary
Exelixis, Inc. announced promising results from the phase 3 pivotal study CONTACT-02, showing a 35% reduction in the risk of disease progression or death in patients with metastatic castration-resistant prostate cancer when treated with cabozantinib in combination with atezolizumab. The study also demonstrated a statistically significant improvement in progression-free survival and a trend for overall survival. Treatment-emergent adverse events occurred in 97% of patients treated with the combination regimen compared with 87% of patients treated with a second novel hormonal therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
clinical trial
-
News
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
Rhea-AI Summary
Exelixis, Inc. (EXEL) will release its fourth quarter and fiscal year 2023 financial results on February 6, 2024, after the markets close. A conference call and webcast will follow to discuss the results and provide a general business update. Access to the event is available via the company’s website. The webcast replay will be archived on the website for one year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
earnings
News
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
Rhea-AI Summary
Bristol Myers Squibb and Exelixis, Inc. announced positive results from the CheckMate -9ER trial, showing that Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib. The combination also demonstrated superior progression-free survival (PFS) and objective response rates (ORR) in patients treated with Opdivo plus CABOMETYX over sunitinib, regardless of risk classification. The four-year follow-up results showed durable and clinically meaningful efficacy, with significant improvements in PFS, OS, ORR, and complete response (CR). No new safety concerns were identified in this follow-up analysis, and the combination regimen also showed benefits in patient subgroups across risk groups. The data will be presented at the ASCO GU 2024 Genitourinary Cancers Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
-
News
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
Rhea-AI Summary
Exelixis, Inc. successfully defended its European Patent number EP2593090 against three opponents, upholding the patent as granted. The patent covers tablet formulations of cabozantinib, including the tablet formulation approved as CABOMETYX® (cabozantinib) tablets by the European Medicines Agency. The decision is specific to the European patent at issue and is subject to appeal to the EPO Technical Boards of Appeal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
none
-
News
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) reported preliminary unaudited financial results for fiscal year 2023, with approximately $1.630 billion in net product revenues. The company also provided guidance for fiscal year 2024, expecting net product revenues of $1,650 million - $1,750 million and R&D expenses of $925 million - $975 million. The appointment of two new board members, corporate restructuring, and a $450 million share repurchase program were also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
earnings
News
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
Rhea-AI Summary
Exelixis, Inc. (Nasdaq: EXEL) will have its President and CEO, Michael M. Morrissey, Ph.D., present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The presentation will be webcast on www.exelixis.com, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
Stock EXEL logo
Exelixis Inc

Nasdaq:EXEL

EXEL Rankings

#993 Ranked by Market Cap
#860 Ranked by Stock Gains
N/A Ranked by Dividends

EXEL Stock Data

6.92B
255.76M
2.34%
88.14%
2.25%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Alameda

About EXEL

exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. our first commercial product, cometriq® (cabozantinib), received its initial regulatory approval in late 2012. we are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer. for more information about the company and potential job opportunities, please visit our website at www.exelixis.com.